SHP1 Cancer Research Results

SHP1, Src Homology region 2 domain-containing Phosphatase-1: Click to Expand ⟱
Source:
Type:
SHP1 is a non-receptor protein tyrosine phosphatase primarily encoded by the gene PTPN6.
Immune Checkpoint Brake, Tumor Suppressor Signaling, and Immune Evasion

– In blood cancers such as leukemia and lymphoma, altered SHP1 expression (often downregulation) is frequently observed.
– Downregulation or loss of SHP1 is often associated with more aggressive disease phenotypes and poorer prognosis.
Direction of Regulation in Cancer 
Two distinct, context-specific directions:
A. Tumor Cells (especially hematologic malignancies): DOWNREGULATED
-Frequently silenced epigenetically (promoter methylation)
-Rarely mutated; loss is regulatory
-Results in unchecked growth and survival signaling

B. Immune Cells within the Tumor Microenvironment: FUNCTIONALLY UPREGULATED
-Actively recruited by inhibitory receptors
-Suppresses T-cell, NK-cell, and myeloid anti-tumor responses
-Promotes immune evasion

This duality is critical to interpret SHP1 correctly.

When SHP1 is lost in tumor cells:
-JAK–STAT signaling becomes hyperactive
-Growth and survival pathways escape negative feedback
-Cells gain a proliferative and survival advantage


Park, Parkinson's Disease (PD): Click to Expand ⟱
Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor and non-motor symptoms, and is due to the degeneration of dopaminergic neurons. It is multifactorial, caused by genetic and environmental factors and currently has no definitive cure.
-CoQ10 deficiency was observed at a higher frequency in Parkinson's disease
Scientific Papers found: Click to Expand⟱
2782- CHr,    Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives
- Review, Var, NA - Review, Stroke, NA - Review, Park, NA
*antiOx↑, *Inflam↓, *hepatoP↑, *neuroP↑, *BioAv↓, *cardioP↑, *lipidLev↓, *RenoP↑, *TNF-α↓, *IL2↓, *PI3K↓, *Akt↓, *ROS↓, *cognitive↑, eff↑, cycD1/CCND1↓, hTERT/TERT↓, VEGF↓, p‑STAT3↓, TumMeta↓, TumCP↓, eff↑, eff↑, IL1β↓, IL6↓, NF-kB↓, ROS↑, MMP↓, Cyt‑c↑, Apoptosis↑, ER Stress↑, Ca+2↑, TET1↑, Let-7↑, Twist↓, EMT↓, TumCCA↑, Casp3↑, Casp9↑, BAX↑, HK2↓, GlucoseCon↓, lactateProd↓, Glycolysis↓, SHP1↑, N-cadherin↓, E-cadherin↑, UPR↑, PERK↑, ATF4↑, eIF2α↑, RadioS↑, NOTCH1↑, NRF2↓, BioAv↑, eff↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

NRF2↓, 1,   ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,  

Core Metabolism/Glycolysis ⓘ

GlucoseCon↓, 1,   Glycolysis↓, 1,   HK2↓, 1,   lactateProd↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   BAX↑, 1,   Casp3↑, 1,   Casp9↑, 1,   Cyt‑c↑, 1,   hTERT/TERT↓, 1,  

Protein Folding & ER Stress ⓘ

eIF2α↑, 1,   ER Stress↑, 1,   PERK↑, 1,   UPR↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,   Let-7↑, 1,   NOTCH1↑, 1,   SHP1↑, 1,   p‑STAT3↓, 1,  

Migration ⓘ

Ca+2↑, 1,   E-cadherin↑, 1,   N-cadherin↓, 1,   TET1↑, 1,   TumCP↓, 1,   TumMeta↓, 1,   Twist↓, 1,  

Angiogenesis & Vasculature ⓘ

ATF4↑, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL1β↓, 1,   IL6↓, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   eff↑, 4,   RadioS↑, 1,  

Clinical Biomarkers ⓘ

hTERT/TERT↓, 1,   IL6↓, 1,  
Total Targets: 41

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   ROS↓, 1,  

Core Metabolism/Glycolysis ⓘ

lipidLev↓, 1,  

Cell Death ⓘ

Akt↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

PI3K↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL2↓, 1,   Inflam↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   cognitive↑, 1,   hepatoP↑, 1,   neuroP↑, 1,   RenoP↑, 1,  
Total Targets: 14

Scientific Paper Hit Count for: SHP1, Src Homology region 2 domain-containing Phosphatase-1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:75  Cells:%  prod#:%  Target#:1331  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page